Effectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review
Patients with inflammatory bowel disease (IBD) increasingly use cannabis. Studies investigating the effectiveness and safety of cannabis as a therapeutic option for IBD have reported conflicting findings, and recent reviews have not incorporated evidence from real-world studies. This systematic review assessed controlled non-interventional studies and interventional trials evaluating the effectiveness of delta-9-tetrahydrocannabinol (THC)-containing cannabis products in patients with IBD. The systematic review procedures—including search strategy across four databases, literature screening, data extraction, qualitative result synthesis, and risk of bias assessment—followed the Cochrane Handbook and adhered to PRISMA-compliant reporting. We used the GRADE approach to rate evidence quality for each outcome.